Russian vaccine arrives this week for human trials

Nellie Chapman
November 16, 2020

Russian Federation registered Sputnik V for public use in August, the first country to do so, though the approval came before the start of the large-scale trial in September.

Speaking to PTI, college principal RB Kamal said the human clinical trials of the vaccine will start from next week. The vaccine will be administered to Stop & Shop customers at no cost.

Khairy said through participation in COVAX, Malaysia would have access to the supply of Covid-19 vaccine of 10% of the country's population and the government was working to get another 60% to meet the national immunisation target for herd immunity to up to 70 per cent of the country's population.

The condition and vitals of the volunteers will be monitored periodically, Kamal said, adding that the data will then be analysed to determine whether the vaccine is successful or not.

Protests Against Nagorno-Karabakh Ceasefire Agreement Continue in Yerevan, Armenia
Since then, Armenia has repeatedly attacked Azerbaijani civilians and forces, even violating three humanitarian cease-fire agreements.


The Ethics Committee of the college has also given permission for the test. He said the effect of the vaccine on the volunteers will be studied for seven months after the same is administered once, twice or thrice within an interval of 21 days.

The South Korean deal marks a second production agreement since Russian Federation said on Wednesday that the vaccine was found to be 92% effective at protecting people from COVID-19 according to interim trial results. In September 2020, Dr. Reddy's and RDIF entered into an agreement for clinical trials of Sputnik-5 vaccine and its distribution in India.

The World Health Organization (WHO) is in discussions with the Russian institute that developed the Sputnik V candidate vaccine against COVID-19 over its potential application for emergency use listing, the United Nations agency said on Thursday.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER